In total, seven studies assessed different oral doses of semaglutide.1521 Additionally, 4 and 9 studies analysed low (0.51mg) and high (1.72.4mg) weekly subcutaneous doses of semaglutide, respectively.6,2334 One study evaluated two active arms: daily oral semaglutide and weekly subcutaneous semaglutide at doses of 0.51mg.22 Overall, 12 studies included all patients with T2DM,1520,22,2426 while another 7 studies considered this condition as an exclusion criterion (instead studying patients with overweight or obesity).6,21,2731 Two studies included patients with or without T2DM.32,34 Across all studies, a history of pancreatitis was consistently regarded as an exclusion criterion
US Boxed Warning: Thyroid C-cell Tumors Strictly contraindicated in patients with a personal or family history of Medullary Thyroid Carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)
doi: 10.7717/peerj.9451 14 Boschi-MullerS.AzzaS.Sanglier-CianferaniS.TalfournierF.Van DorsselearA.BranlantG
doi: 10.3390/ijms23105719
